MaaT Pharma SA (EPA: MAAT)
France
· Delayed Price · Currency is EUR 8.30
+0.14 (1.72%)
Nov 19, 2024, 5:35 PM CET
MaaT Pharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Operating Revenue | 2.57 | 2.23 | 1.43 | 0.97 | - | - | Upgrade
|
| Other Revenue | - | - | - | - | - | 0.09 | Upgrade
|
| Revenue | 2.57 | 2.23 | 1.43 | 0.97 | - | 0.09 | Upgrade
|
| Revenue Growth (YoY) | 11.11% | 55.80% | 47.12% | - | - | -89.99% | Upgrade
|
| Cost of Revenue | 1.13 | 0.88 | 0.64 | 0.33 | 0.03 | 4.75 | Upgrade
|
| Gross Profit | 1.44 | 1.35 | 0.79 | 0.64 | -0.03 | -4.66 | Upgrade
|
| Selling, General & Admin | 5.93 | 5.38 | 4.43 | 2.92 | 1.27 | 1.39 | Upgrade
|
| Research & Development | 23.54 | 20.49 | 13.98 | 8.96 | 6.05 | - | Upgrade
|
| Other Operating Expenses | -3.86 | -4.58 | -4.06 | -2.34 | -2.1 | -0.07 | Upgrade
|
| Operating Expenses | 25.6 | 21.29 | 14.34 | 9.54 | 5.22 | 1.51 | Upgrade
|
| Operating Income | -24.16 | -19.94 | -13.56 | -8.89 | -5.25 | -6.17 | Upgrade
|
| Interest Expense | -0.5 | -0.4 | -0.19 | -0.12 | -0.05 | -0.07 | Upgrade
|
| Interest & Investment Income | 0.54 | 0.64 | 0.05 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | - | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.02 | -0.01 | -0 | -0 | Upgrade
|
| Pretax Income | -24.14 | -19.72 | -13.71 | -9.02 | -5.3 | -6.24 | Upgrade
|
| Income Tax Expense | - | - | - | - | - | -1.11 | Upgrade
|
| Net Income | -24.14 | -19.72 | -13.71 | -9.02 | -5.3 | -5.13 | Upgrade
|
| Net Income to Common | -24.14 | -19.72 | -13.71 | -9.02 | -5.3 | -5.13 | Upgrade
|
| Shares Outstanding (Basic) | 12 | 11 | 10 | 2 | 1 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 11 | 10 | 2 | 1 | 1 | Upgrade
|
| Shares Change (YoY) | 13.16% | 14.89% | 307.65% | 135.06% | - | - | Upgrade
|
| EPS (Basic) | -2.03 | -1.73 | -1.39 | -3.72 | -5.14 | -4.97 | Upgrade
|
| EPS (Diluted) | -2.03 | -1.73 | -1.39 | -3.72 | -5.14 | -5.66 | Upgrade
|
| Free Cash Flow | -18.94 | -19.76 | -13.27 | -8.17 | -6.16 | - | Upgrade
|
| Free Cash Flow Per Share | -1.59 | -1.74 | -1.34 | -3.37 | -5.97 | - | Upgrade
|
| Gross Margin | 56.01% | 60.59% | 55.10% | 66.05% | - | - | Upgrade
|
| Operating Margin | -939.87% | -895.11% | -947.97% | -914.92% | - | -6913.78% | Upgrade
|
| Profit Margin | -938.86% | -884.96% | -958.95% | -927.88% | - | -5744.77% | Upgrade
|
| Free Cash Flow Margin | -736.76% | -887.03% | -927.76% | -840.23% | - | - | Upgrade
|
| EBITDA | -23.94 | -19.74 | -13.32 | -8.71 | -5.15 | -6.11 | Upgrade
|
| D&A For EBITDA | 0.22 | 0.2 | 0.24 | 0.18 | 0.1 | 0.07 | Upgrade
|
| EBIT | -24.16 | -19.94 | -13.56 | -8.89 | -5.25 | -6.17 | Upgrade
|
| Revenue as Reported | - | - | - | - | - | 0.19 | Upgrade
|
| Advertising Expenses | - | 0.24 | 0.19 | 0.15 | 0.1 | 0.15 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.